Tumor galectinology: Insights into the complex network of a family of endogenous lectins

Glycoconjugate Journal

Volumn 20, Issue 4, 2003, Pages 227-238

  Lahm, Harald ^a   André, Sabine ^b   Hoeflich, Andreas ^b   Kaltner, Herbert ^b   Siebert, Hans Christian ^b   Sordat, Bernard ^c   Von Der Lieth, Claus Wilhelm ^d   Wolf, Eckhard ^b   Gabius, Hans Joachim ^b  

^a Immunol Molec Biology Laboratory   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Galectin; Invasion; Metastasis; Tumor diagnosis; Tumor marker

Indexed keywords

BETA GALACTOSIDE; ECALECTIN; GALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 4; GALECTIN 8; LECTIN; MESSENGER RNA; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL SURFACE; CELL TYPE; COLON CARCINOGENESIS; CONJUGATE; CYTOLOGY; DNA FINGERPRINTING; GEL ELECTROPHORESIS; GENE EXPRESSION; GENE IDENTIFICATION; GENE INSERTION; GENE MAPPING; GROWTH REGULATION; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; MONITORING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TANDEM REPEAT; TUMOR; TUMOR CELL;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; CELL DIVISION; GALECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

INSERTION SEQUENCES;

EID: 4143099262     PISSN: 02820080     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:GLYC.0000025817.24297.17     Document Type: Review

References (119)

1. Hakomori S-i, Murakami WT, Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines, Proc Natl Acad Sci USA 59, 254-61 (1968).
2. Yogeeswaran G, Cell surface glycolipids and glycoproteins in malignant transformation, Adv Cancer Res 38, 289-350 (1983).
3. Smets LA, van Beek WP, Carbohydrates of the tumor cell surface, Biochim Biophys Acta 738, 237-49 (1984).
4. Alhadeff JA, Malignant cell glycoproteins and glycolipids, Crit Rev Oncol Hematol 9, 37-107 (1989).
5. Hakomori S-i, Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens, Adv Cancer Res 52, 257-331 (1989).
6. Dabelsteen E, Cell surface carbohydrates as prognostic markers in human carcinomas, J Pathol 179, 358-69 (1996).
7. Gabius H-J, Concepts of tumor lectinology, Cancer Investig 15, 454-64 (1997).
8. Kim YJ, Varki A, Perspectives on the significance of altered glycosylation of glycoproteins in cancer, Glycoconjugate J 14, 569-76 (1997).
9. Brockhausen I, Schutzbach J, Kuhns W, Glycoproteins and their relationship to human disease, Acta Anat 161, 36-78 (1998).
10. Hakomori S-i, Cancer-associated glycosphingolipid antigens: Their structure, organization and function, Acta Anat 161, 79-90 (1998).
11. Kobata A, A retrospective and prospective view of glycopathology, Glycoconjugate J 15, 323-31 (1998).
12. Dennis JW, Granovsky M, Warren CE, Glycoprotein glycosylation and cancer progression, Biochim Biophys Acta 1473, 21-34 (1999).
13. Reuter G, Gabius H-J, Eukaryotic glycosylation - whim of nature or multipurpose tool? Cell Mol Life Sci 55, 368-422 (1999).
14. Scanlin TF, Glick MC, Terminal glycosylation and disease: Influence on cancer and cystic fibrosis, Glycoconjugate J 17, 617-26 (2000).
15. Coon JS, Weinstein RS, Blood group-related antigens as markers of malignant potential and heterogeneity in human carcinomas, Hum Pathol 17, 1089-106 (1986).
16. Caselitz J, Lectins and blood group substances as "tumor markers", Curr Top Pathol 77, 245-77 (1987).
17. Damjanov I, Lectin cytochemistry and histochemistry, Lab Invest 57, 5-20 (1987).
18. Walker RA, The use of lectins in histopathology, Pathol Res Pract 185, 826-35 (1989).
19. Rüdiger H, Gabius H-J, Plant lectins, Glycoconjugate J 18, 589-613 (2001).
20. Gabius H-J, André S, Kaltner H, Siebert H-C, The sugar code: Functional lectinomics, Biochim Biophys Acta 1572, 165-77 (2002).
21. Laine RA, The information-storing potential of the sugar code. In Glycosciences: Status and Perspectives, edited by Gabius H-J, Gabius S (Chapman & Hall, London, Weinheim, 1997), pp. 1-14.
22. Kaltner H, Stierstorfer B, Animal lectins as cell adhesion molecules, Acta Anat 161, 162-79 (1998).
23. Gabius H-J, Biological information transfer beyond the genetic code: The sugar code, Naturwissenschaften 87, 108-21 (2000).
24. Hirabayashi J, Kasai K-i, Glycomics, coming of age! Trends Glycosci Glycotechnol 12, 1-5 (2000).
25. Rüdiger H, Siebert H-C, Solís D, Jiménez-Barbero J, Romero A, von der Lieth C-W, Díaz-Mauriño T, Gabius H-J, Medicinal chemistry based on the sugar code: Fundamentals of lectinology and experimental strategies with lectins as targets, Curr Med Chem 7, 389-416 (2000).
26. Gabius H-J, Engelhardt R, Cramer F, Endogenous tumor lectins: A new class of tumor markers and targets for therapy? Med Hypotheses 18, 47-50 (1985).
27. Siebert H-C, André S, Asensio JL, Cañada FJ, Dong X, Espinosa J-F, Frank M, Gilleron M, Kaltner H, Kozár T, Bovin NV, von der Lieth C-W, Vliegenthart JFG, Jiménez-Barbero J, Gabius H-J, A new combined computational and NMR-spectroscopical strategy for the identification of additional conformational constraints of the bound ligand in an aprotic solvent, ChemBioChem 1, 181-95 (2000).
28. Loris R, Principles of structures of animal and plant lectins, Biochim Biophys Acta 1572, 198-208 (2002).
29. Gabius H-J, Gabius S, Zemlyanukhina TV, Bovin NV, Brinck U, Danguy A, Joshi SS, Kayser K, Schottelius J, Sinowatz F, Tietze LF, Vidal-Vanaclocha F, Zanetta J-P, Reverse lectin histochemistry: Design and application of glycoligands for detection of cell and tissue lectins, Histol Histopathol 8, 369-83 (1993).
30. Danguy A, Decaestecker C, Genten F, Salmon I, Kiss R, Application of lectins and neoglycoconjugates in histology and pathology, Acta Anat 161, 206-18 (1998).
31. Gabius H-J, Glycohistochemistry: The why and how of detection and localization of endogenous lectins, Anat Histol Embryol 30, 3-31 (2001).
32. Lee JS, Ro JY, Sahin AA, Hong WK, Brown BW, Mountain CF, Hittelman WN, Expression of blood-group antigen A - a favorable prognostic factor in non-small-cell lung cancer, N Engl J Med 324, 1084-90 (1991).
33. Kayser K, Bovin NV, Korchagina EY, Zeilinger C, Zeng F-Y, Gabius H-J, Correlation of expression of binding sites for synthetic blood group A-, B-, and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma, Eur J Cancer 30A, 653-7 (1994).
34. Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ, Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer, Clin Cancer Res 3, 87-93 (1997).
35. Gabius H-J, Wosgien B, Brinck U, Schauer A, Localization of endogenous β-galactoside-specific lectins by neoglycoproteins, lectin-binding tissue glycoproteins and antibodies and of accessible lectin-specific ligands by a mammalian lectin in human breast cancer, Pathol Res Pract 187, 839-47 (1991).
36. Gabius H-J, Kohnke-Godt B, Leichsenring M, Bardosi A, Heparin-binding lectin of human placenta as a tool for histochemical ligand localization and ligand isolation, J Histochem Cytochem 39, 1249-56 (1991).
37. Amado M, Almeida R, Schwientek T, Clausen H, Identification and characterization of large galactosyltransferase gene families: Galactosyltransferases for all functions, Biochim Biophys Acta 1473, 35-53 (1999).
38. Furukawa K, Sato T, β1,4-Galactosylation of N-glycans is a complex process, Biochim Biophys Acta 1473, 54-66 (1999).
39. Gastinel LN, Galactosyltransferases: A structural overview of their function and reaction mechanisms, Trends Glycosci Glycotechnol 13, 131-45 (2001).
40. Teichberg VI, Silman I, Beitsch DD, Resheff G, A β-galactoside binding protein from electric organ tissue of Electrophorus electricus, Proc Natl Acad Sci USA 72, 1383-7 (1975).
41. Gabius H-J, Engelhardt R, Cramer F, Bätge R, Nagel GA, Pattern of endogenous lectins in a human epithelial tumor, Cancer Res 45, 253-7 (1985).
42. Cooper DNW, Galectinomics: Finding themes in complexity, Biochim Biophys Acta 1572, 209-31 (2002).
43. Kopitz J, von Reitzenstein C, Burchert M, Cantz M, Gabius H-J, Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture, J Biol Chem 273, 11205-11 (1998).
44. Gabius H-J, Probing the cons and pros of lectin-induced immunomodulation: Case studies for the mistletoe lectin and galectin-1, Biochimie 83, 659-66 (2001).
45. Kopitz J, von Reitzenstein C, André S, Kaltner H, Uhl J, Ehemann V, Cantz M, Gabius H-J, Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3, J Biol Chem 276, 35917-23 (2001).
46. Liu F-T, Patterson RJ, Wang JL, Intracellular functions of galectins, Biochim Biophys Acta 1572, 263-73 (2002).
47. Rabinovich GA, Rubinstein N, Toscano M, Role of galectins in inflammatory and immunomodulatory processes, Biochim Biophys Acta 1572, 274-84 (2002).
48. Gabius H-J, Brehler R, Schauer A, Cramer F, Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas, Virch Arch [Cell Pathol] 52, 107-15 (1986).
49. Itzkowitz SH, Galectins: Multipurpose carbohydrate-binding proteins implicated in tumor biology, Gastroenterology 113, 2003-5 (1997).
50. Ohannesian DW, Lotan R, Galectins in tumor cells. In Glycosciences: Status and Perspectives, edited by Gabius H-J, Gabius S (Chapman & Hall, London-Weinheim, 1997), pp. 459-69.
51. André S, Kojima S, Yamazaki N, Fink C, Kaltner H, Kayser K, Gabius H-J, Galectins-1 and -3 and their ligands in tumor biology, J Cancer Res Clin Oncol 125, 461-74 (1999).
52. Danguy A, Camby I, Kiss R, Galectins and cancer, Biochim Biophys Acta 1572, 285-93 (2002).
53. Lahm H, André S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E, Gabius H-J, Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures, J Cancer Res Clin Oncol 127, 375-86 (2001).
54. Lahm H, André S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E, Gabius H-J, Molecular biological fingerprinting of human lectin expression by RT-PCR, Methods Enzymol 362, 287-97 (2003).
55. Polyak K, Xia Y, Zweier JL, Kinzler KM, Vogelstein B, A model for p53-induced apoptosis, Nature 389, 300-5 (1997).
56. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, Kodama T, Aburatani H, Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes, Cancer Res 61, 889-95 (2001).
57. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector J-C, Zick Y, Salmon I, Danguy A, Kiss R, Gabius H-J, Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor, Gut 50, 392-401 (2002).
58. Nagy N, Legendre H, Engels O, André S, Kaltner H, Wasano K, Zick Y, Pector J-C, Decaestecker C, Gabius H-J, Salmon I, Kiss R, Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting, Cancer 97, 1849-58 (2003).
59. Kayser K, Zink S, Schneider T, Dienemann H, André S, Kaltner H, Schüring M-P, Zick Y, Gabius H-J, Benign metastasizing leiomyoma of the uterus: Documentation of clinical, immunohistochemical and lectin-histochemical data for ten cases, Virchows Arch 437, 284-92 (2000).
60. Camby I, Belot N, Rorive S, Lefranc F, Maurage C-A, Lahm H, Kaltner H, Hadari YR, Ruchoux M-M, Brotchi J, Zick Y, Salmon I, Gabius H-J, Kiss R, Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration, Brain Pathol 11, 12-26 (2001).
61. Danguy A, Rorive S, Decaestecker C, Bronckart Y, Kaltner H, Hadari YR, Goren R, Zick Y, Pétein M, Salmon I, Gabius H-J, Kiss R, Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system, Histol Histopathol 16, 861-8 (2001).
62. Sheikholeslam-Zadeh R, Decaestecker C, Delbrouck C, Danguy A, Salmon I, Zick Y, Kaltner H, Hassid S, Gabius H-J, Kiss R, Choufani G, The levels of expression of galectin-3, but not of Galectins-1 and -8, correlate with apoptosis in human cholesteatomas, Laryngoscope 111, 1042-7 (2001).
63. Wollina U, Graefe T, Feldrappe S, André S, Wasano K, Kaltner H, Zick Y, Gabius H-J, Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma, J Cancer Res Clin Oncol 128, 103-10 (2002).
64. Gabius H-J, Animal lectins, Eur J Biochem 243, 543-76 (1997).
65. Dahms NM, Hancock MK, P-type lectins, Biochim Biophys Acta 1572, 317-40.
66. Kilpatrick DC, Animal Lectins: An historical introduction and overview, Biochim Biophys Acta 1572, 187-97 (2002).
67. Wada J, Kanwar YS, Identification and characterization of galectin-9, a novel β-galactoside-binding mammalian lectin, J Biol Chem 272, 6078-86 (1997).
68. Suk K, Hwang D-Y, Lee M-S, Natural autoantibody to galectin-9 in normal human serum, J Clin Immunol 19, 158-65 (1999).
69. Lahm H, Hoeflich A, André S, Sordat B, Kaltner H, Wolf E, Gabius H-J, Gene expression of galectin-9/ecalectin, a potent eosinophil chemoattractant, and/or the insertional isoform in human colorectal carcinoma cell lines and detection of frame-shift mutations for protein sequence truncations in the second functional lectin domain, Int J Oncol 17, 519-24 (2000).
70. Türeci Ö, Schmitt H, Fadle N, Pfreundschuh M, Sahin U, Molecular definition of a novel galectin which is immunogenic in patients with Hodgkin's disease, J Biol Chem 272, 6416-22 (1997).
71. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M, Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T-lymphocytes, J Biol Chem 273, 16976-84 (1998).
72. Matsushita N, Nishi N, Seki M, Matsumoto R, Kuwabara I, Liu F-T, Hata Y, Nakamura T, Hirashima M, Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction, J Biol Chem 275, 8355-60 (2000).
73. Brewer CF, Binding and cross-linking properties of galectins, Biochim Biophys Acta 1572, 255-62 (2002).
74. Dazord L, Bourel D, Martin A, Lecorre R, Bourguet P, Bohy J, Saccavini JC, Delaval P, Louvet M, Toujas L, A monoclonal antibody (Po66) directed against human lung squamous cell carcinoma immunolocalization of tumour xenografts in nude mice, Cancer Immunol Immunother 24, 263-8 (1987).
75. Brichory F, Collet B, Pineau C, Desrues B, Toujas L, Pennec JP, Dazord L, Purification of a tumoral marker recognized by monoclonal antibody Po66 and associated with human lung squamous cell carcinoma, Int J Biol Markers 11, 148-52 (1996).
76. Su ZZ, Lin J, Shen R, Fischer PE, Goldstein NI, Fischer PB, Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family, Proc Natl Acad Sci USA 93, 7252-7 (1996).
77. Hadari Y, Eisenstein M, Zakut R, Zick Y, Galectin-8: On the road from structure to function, Trends Glycosci Glycotechnol 9, 103-12 (1995).
78. Bassen R, Brichory F, Caulet-Maugendre S, Bidon N, Delaval P, Desrues B, Dazord L, Expression of Po66-CBP, a type-8 galectin, in different healthy, tumoral and peritumoral tissues, Anticancer Res 19, 5429-33 (1999).
79. Bidon N, Brichory F, Hanash S, Bourguet P, Dazord L, Le Pennec JP, Two messenger RNAs and five isoforms for Po66-CBP, a galectin-8 homolog in a human lung carcinoma cell line, Gene 274, 253-62 (2001).
80. Gopalkrishnan RV, Roberts T, Tuli S, Kang D, Christiansen KA, Fisher PB, Molecular characterization of prostate carcinoma tumor antigen-1, PCTA- 1, a human galectin-8 related gene, Oncogene 19, 4405-16 (2000).
81. Hadari YR, Arbel-Goren R, Levy Y, Amsterdam A, Alon R, Zakut R, Zick Y, Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis, J Cell Sci 113, 2385-97 (2000).
82. Bidon N, Brichory F, Bourguet P, Le Pennec JP, Dazord L, Galectin-8: A complex sub-family of galectins (Review), Int J Mol Med 8, 245-50 (2001).
83. Cajot JF, Sordat I, Silvestre T, Sordat B, Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells, Cancer Res 57, 2953-7 (1997).
84. Siebert H-C, Adar R, Arango R, Burchert M, Kaltner H, Kayser G, Tajkhorshid E, von der Lieth C-W, Kaptein R, Sharon N, Vliegenthart JFG, Gabius H-J, Involvement of laser photo CIDNP (chemically induced dynamic nuclear polarization)-reactive amino acid side chains in ligand binding by galactoside-specific lectins in solution. Similarities in the role of tryptophan/tyrosine residues for ligand binding between a plant agglutinin and mammalian/avian galectins and the detection of an influence of single-site mutagenesis on surface presentation of spatially separated residues, Eur J Biochem 249, 27-38 (1997).
85. von der Lieth C-W, Siebert H-C, Kozár T, Burchert M, Frank M, Gilleron M, Kaltner H, Kayser G, Tajkhorshid E, Bovin NV, Vliegenthart JFG, Gabius H-J, Lectin ligands: New insights into their conformations and their dynamic behavior and the discovery of conformer selection by lectins, Acta Anat 161, 91-109 (1998).
86. Caulet-Maugendre S, Birolleau S, Corbineau H, Bassen R, Desrues B, Bidon N, Delaval P, Ramee MP, Brichory F, Dazord L, Immimohistochemical expression of the intracellular component of galectin-8 in squamous cell metaplasia of the bronchial epithelium in neoplastic and benign processes, Pathol Res Pract 197, 797-801 (2001).
87. Henno S, Brichory F, Langanay T, Desrues B, Bidon N, Delaval P, Ramee MP, Dazord L, Caulet-Maugendre S, Expression of Po66-CBP, a galectin-8, in different types of primary and secondary broncho-pulmonary tumors, Oncol Rep 9, 177-80 (2002).
88. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y, Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation, Oncogene 20, 7486-93 (2001).
89. Elad-Sfadia G, Haklai R, Ballan E, Gabius H-J, Kloog Y, Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase, J Biol Chem 277, 37169-75 (2002).
90. Levy Y, Arbel-Goren R, Hadari YR, Eshhar S, Ronen D, Elhanany E, Geiger B, Zick Y, Galectin-8 functions as a matricellular modulator of cell adhesion, J Biol Chem 276, 31285-95 (2001).
91. Gorski JP, Liu F-T, Artigues A, Castagna LF, Osdoby P, New alternatively spliced form of galectin-3, a member of the β-galactoside-binding animal lectin family, contains a predicted transmembrane-spanning domain and a leucine zipper motif, J Biol Chem 277, 18840-8 (2002).
92. Ariizumi K, Shen GL, Shikano S, Ritter R, 3rd, Zukas P, Edelbaum D, Morita A, Takashima A, Cloning of a second dendritic cell-associated C-type lectin (dectin-2) and its alternatively spliced isoforms, J Biol Chem 275, 11957-63 (2000).
93. Hernanz-Falcon P, Arce I, Roda-Navarro P, Fernandez-Ruiz E, Cloning of human DECTIN-1, a novel C-type lectin-like receptor gene expressed on dendritic cells, Immunogenetics 53, 288-95 (2001) Erratum in: Immunogenetics 53(6) 518 (2001).
94. Mummidi S, Catano G, Lam L, Hoefle A, Telles V, Begum K, Jimenez F, Ahuja SS, Ahuja SK, Extensive repertoire of membrane-bound and soluble dendritic cell-specific ICAM-3-grabbing nonintegrin 1 (DC-SIGN1) and DC-SIGN2 isoforms, J Biol Chem 276, 33196-212 (2001).
95. Yokota K, Takashima A, Bergstresser PR, Ariizumi K, Identification of a human homologue of the dendritic cell-associated C-type lectin-1, dectin-1, Gene 272, 51-60 (2001).
96. Gunnersen JM, Spirkoska V, Smith PE, Danks RA, Tan SS, Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression, Glia 32, 146-54 (2000).
97. Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y, Kirino T, Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells, J Neurosci Res 59, 722-30 (2000).
98. Rorive S, Belot N, Decaestecker C, Lefranc F, Gordower L, Micik S, Maurage C-A, Kaltner H, Ruchoux M-M, Danguy A, Gabius H-J, Salmon I, Kiss R, Camby I, Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma, GLIA 33, 241-55 (2001).
99. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius H-J, Kiss R, Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases, J Neuropathol Exp Neurol 61, 585-96 (2002).
100. - leukemic T cells from patients with Sézaiy syndrome are protected from galectin-1-triggered T cell death, Leukemia 16, 840-5 (2002).
101. André S, Cejas Ortega PJ, Alamino Perez M, Roy R, Gabius H-J, Lactose-containing starburst dendrimers: Influence of dendrimer generation and binding-site orientation of receptors (plant/animal lectins and immunoglobulins) on binding properties, Glycobiology 9, 1253-61 (1999).
102. André S, Frisch B, Kaltner H, Desouza DL, Schuber F, Gabius H-J, Lectin-mediated drug targeting. Selection of valency, sugar type (Gal/Lac) and spacer length for cluster glycosides as parameters to distinguish ligand binding to C-type asialoglycoprotein receptors and galectins, Pharmaceut Res 17, 985-90 (2000).
103. Yamazaki N, Kojima S, Bovin NV, André S, Gabius S, Gabius H-J, Endogenous lectins as targets for drug delivery, Adv Drug Deliv Rev 43, 225-44 (2000).
104. André S, Pieters RJ, Vrasidas I, Kaltner H, Kuwabara I, Liu F-T, Liskamp RMJ, Gabius H-J, Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to various glycoproteins, lactose maxiclusters and cell surface glycoconjugates, ChemBioChem 2, 822-30 (2001).
105. Nangia-Makker P, Conklin J, Hogan V, Raz A, Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents, Trends Mol Med 8, 187-92 (2002).
106. Sörme P, Qian Y, Nyholm PG, Leffler H, Nilsson UJ, Low micromolar inhibitors of galectin-3 based on 3′-derivatization of N-acetyllactosamine, ChemBioChem 3, 183-9 (2002).
107. Vrasidas I, André S, Valentini P, Böck C, Lensch M, Kaltner H, Liskamp RMJ, Gabius H-J, Pieters RJ, Rigidified multivalent lactose molecules and their interactions with mammalian galectins: A route to selective inhibitors, Org Biomol Chem 1, 803-10 (2003).
108. Yilmaz A, Gaide A-C, Sordat B, Borbenyi Z, Lahm H, Imam A, Schreyer M, Odartchenko N, Malignant progression of SV40-immortalised human milk epithelial cells, Br J Cancer 68, 868-73 (1993).
109. Carrel S, Sordat B, Merenda C, Establishment of a cell line (Co-115) from a human colon carcinoma transplanted into nude mice, Cancer Res 36, 3978-84 (1976).
110. Cajot JF, Sordat I, Silvestre T, Sordat B, Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells, Cancer Res 57, 2593-7 (1997).
111. Bepler G, Rotsch M, Jacques G, Haeder M, Heymanns J, Hartogh G, Kiefer P, Havemann K, Peptides and growth factors in small cell lung cancer: Production, binding sites and growth effects, J Cancer Res Clin Oncol 114, 235-44 (1988).
112. Bepler G, Bading H, Heimann B, Kiefer P, Havemann K, Moelling K, Expression of p64 c-myc and neuroendocrine properties define three subclasses of small cell lung cancer, Oncogene 4, 45-50 (1989).
113. Wörmann B, Anderson JM, Liberty JA, Gajl-Peczalska K, Brunning RD, Silberman TL, Arthur DC, Lebien TW, Establishment of a leukemic cell model for studying human pre-B to B-cell differentiation, J Immunol 142, 110-7 (1989).
114. Gabius S, Joshi SS, Gabius H-J, Sharp JG, Establishment, characterization and determination of cell surface sugar receptor (lectin) expression by neoglycoenzymes of a human myeloid marker-expressing B lymphoblastoid cell line, Anticancer Res 11, 793-800 (1991).
115. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, Faldella A, Rege-Chambrin G, Thunberg U, Nilsson K, Caligaris-Cappio F, MEC1 and MEC2: Two new cell lines from B-chronic lymphocytic leukemia in prolymphocytoid transformation, Leukemia Res 23, 127-36 (1999).
116. Hasselmann DO, Rappl G, Tilgen W, Reinhold U, Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum, Clin Chem 47, 1488-9 (2001).
117. Cattel L, Delprino L, Brusa P, Dosio F, Comoglio PM, Prat M, Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines, Cancer Immunol Immunother 27, 233-40 (1988).
118. Bosserhoff AK, Gläßl A, Stolz W, Buettner R, Detection of telomerase activity in skin, melanocytic nevi, and melanoma by telomerase PCR ELISA, Biochemica 3, 16-8 (1997)
119. Bazzoni F, Regalia E, Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-α, Cancer Res 61, 1050-7 (2001).